MedReleaf Announces Inclusion to the North American Marijuana Index and Horizon's Medical Marijuana Life Sciences ETF

MARKHAM, ON, Sept. 20, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has been added to the North American Marijuana Index (the "Index") as part of its quarterly rebalancing, and by extension, included in the Horizon Medical Marijuana Life Sciences ETF (TSX: HMMJ) ("HMMJ").

"MedReleaf's addition to the North American Marijuana Index is a recognition of our position as one of the industry's largest and most respected cannabis producers. We have achieved this position through our relentless focus on serving our patients and we will continue to focus on driving growth and profitability in our business to create long-term shareholder value," said Neil Closner, CEO of MedReleaf. "Our inclusion in Horizon's Medical Marijuana Life Sciences ETF provides another avenue for investors to participate in our growth."

The HMMJ is the world's first exchange-traded fund to offer direct exposure to the performance of a basket of North American publicly listed companies with significant business activities in the cannabis industry. The HMMJ seeks to replicate, to the extent possible, the performance of the Index, net of expenses. It is important to note that that HMMJ may not hold all of the constituent names in the Index. Constituents of the Index are listed on North America's public equity markets with business activities that include biopharmaceuticals, medical manufacturing, distribution, bioproducts and other ancillary businesses to the cannabis industry. To be eligible for inclusion a stock must meet minimum asset and liquidity thresholds, and no single stock may exceed 10% of the weight of the Index when rebalanced.

About MedReleaf Corp.

MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world.  The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.  Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

For more information on MedReleaf, its products, research and how the Company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.

SOURCE MedReleaf Corp.

Dennis Fong, Investor Relations, [email protected], 416-283-9930